Reporting side effects
As a patient, you have the right to report side effects of medicines directly to the authorities. The EMA has published a leaflet in all EU languages on how to report side effects for yourself or on behalf of someone in your care. You usually do this by filling in a form available online or from your doctor or pharmacist.
You can also use the European database of suspected adverse drug reaction reports to see information on suspected side effects reported with thousands of different medicines.
Involvement of patients and consumers in the Agency's activities
Patients and consumers are the end-users of the medicines that the European Medicines Agency evaluates, so they are key stakeholders with specific knowledge and expertise to offer the Agency.
The Agency is committed to maintaining a strong working relationship with patients and consumers and is interacting with a growing number of patients’ and consumers’ organisations.
See more information on the Agency's work with patients and consumers.
Searching for medicines by therapeutic area
It is possible to browse for a medicine by therapeutic area. The Agency categorises each medicine it assesses using a taxonomy which can be easily browsed. Go to European public assessment reports (EPARs) and use the 'browse by therapeutic area' tab.
Beware of falsified medicines!
Falsified medicines are fake medicines that may enter the supply chain illegally. Be careful about the way you buy medicines. Find more information on falsified medicines.
Search for herbal medicines
The Agency is responsible for supporting the harmonisation of herbal medicinal products in Europe. Search for herbal medicines assessed by the Agency's Committee on Herbal Medicinal Products.
News for patients and carers
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 17-20 November 2014
Ten new medicines, two orphans, recommended for approval ... Read more
New oral treatment option for rare debilitating genetic disease ... Read more
Additional treatment options with high cure rates to be available to patients ... Read more
Change in status to facilitate access for women in the European Union ... Read more
European Medicines Agency recommends measures to reduce risk of heart problems with Corlentor/Procoralan (ivabradine)
The European Medicines Agency (EMA) has completed a review of Corlentor/Procoralan (ivabradine) and has made recommendations aimed at reducing the risk of heart problems, including heart attack and bradycardia (excessively low heart rate), in patients taking the medicine for angina. ... Read more
- See all News for patients and carers
Events of interest
European Medicines Agency Human Scientific Committees' Working Parties with Patients’ and Consumers’ Organisations (PCWP) and Healthcare Professionals’ Organisations (HCPWP) joint meeting
This is a joint meeting with representatives from patients’, consumers’ and healthcare professionals’ organisations. Participants will be updated on a number of European Medicines Agency (EMA) initiatives including EMA adaptive licensing pilot project, health-technology assessment-EMA interaction, assessing the impact of pharmacovigilance and EMA communication on medication errors. The PCWP/HCPWP work programmes 2015 will also be discussed. Registration by invitation only. ... Read more
Committee for Advanced Therapies (CAT) and the German Society for Transfusion Medicine and Immunohaematology (DGTI) workshop on advanced-therapy medicinal products: How to bring cell-based medicinal products successfully to the market
The workshop is co-organised by the European Medicines Agency's (EMA's) Committee for Advanced Therapies (CAT) and the German Society for Transfusion Medicine and Immunohaematology (DGTI) in collaboration with the German Stem Cell Network (GSCN) and aims to strengthen dialogue between CAT and the advanced-therapy-medicinal-product (ATMP) developers in industry, academia and hospitals and to facilitate ATMP development and access to the registration procedure. The workshop will allow for the attendees to learn about the development and authorisation of cell-based ATMPs in the European Union and the role of the CAT; to learn about the support provided by EMA and the CAT to ATMP developers; to understand the criteria that CAT applies for the classification of ATMPs; and to hear about CAT’s considerations and recent interactions with experts on cell-based therapies for cardiac repair. It will also allow to interact directly with the Regulators in an open forum discussion. ... Read more
Medicines and Healthcare Products Regulatory Agency information day: Medical Dictionary for Regulatory Activities in the pharmacovigilance regulatory process
This information day will provide attendees with a highlight of the latest Medical Dictionary for Regulatory Activities (MedDRA) initiatives and developments. This will includes an outline of various efforts of the MedDRA Maintenance and Support Services Organization (MSSO) to support interoperability of MedDRA with other terminologies specifically in the healthcare domain and the use of MedDRA in coding and analysing medication errors. Places limited. ... Read more
Eighth stakeholders forum on the implementation of the pharmacovigilance legislation: Building on two years of operation
The meeting will allow attendees to discuss the current status of implementation, building on two years of operation of the European Union pharmacovigilance system as well as various on-going EU-wide initiatives. Registration by invitation only. ... Read more
30/09/2014 - 01/10/2014
Joint European Forum for Good Clinical Practice / Drug Information Association / European Medicines Agency: Better medicines for children conference
The aim of this conference is to discuss on a high level how the European Union paediatric regulation is working and how it contributes to children’s health. This will include a discussion on the preparedness for the 10-year report, strategic thoughts within the European Medicines Agency on how to streamline paediatric development and a session dedicated to paediatric oncology. Experts from all involved parties will be present, and on day one, participants will discuss more specialised issues in four breakout sessions. Places limited. ... Read more
- See all Events of interest